Inclisiran
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 623 publications
Drugs for hypercholesterolemia.
Journal: The Medical letter on drugs and therapeutics
Published: June 01, 2026
Comparison chart: Some non-statin lipid-lowering drugs.
Journal: The Medical letter on drugs and therapeutics
Published: June 01, 2026
Current and Future Perspectives of LDL-C Lowering Therapies 2026.
Journal: Journal of atherosclerosis and thrombosis
Published: May 27, 2026
Erratum: Inclisiran safety and efficacy in real-world clinical practice: results of a retrospective observational investigation.
Journal: Journal of cardiovascular medicine (Hagerstown, Md.)
Published: May 26, 2026
Inclisiran in CKD: A Therapeutic Answer to a Persistent Treatment Gap.
Journal: Journal of the American Society of Nephrology : JASN
Published: May 20, 2026
Low-Density Lipoprotein Cholesterol Lowering With Inclisiran Plus Usual Care in Recent Acute Coronary Syndrome: VICTORION-INCEPTION, a Randomized, Controlled, Open-Label Trial.
Journal: Journal of the American Heart Association
Published: May 14, 2026
Theoretical Cost-Effectiveness of PCSK9 Inhibitors in Stroke Due to Intracranial Atherosclerosis.
Journal: JAMA network open
Published: May 05, 2026
Lerodalcibep (Lerochol) for hypercholesterolemia.
Journal: The Medical letter on drugs and therapeutics
Published: May 02, 2026
Evolution of siRNA Therapeutics: From Mechanistic Foundations to Clinical Expansion.
Journal: Pharmaceutics
Published: April 16, 2026
Novel Therapies, Residual Risk, Familial Hypercholesterolemia, and Digital Tools: Multispecialty Insights from a Dyslipidemia Management Survey.
Journal: Journal of clinical medicine
Published: April 08, 2026
Long-Acting Lipid-Lowering Injectables and Behavioral Moral Hazard: A Systematic Review of Adherence, Lifestyle Measurement, and Structural Evidence Gaps.
Journal: Healthcare (Basel, Switzerland)
Published: April 05, 2026
Real-world lipid outcomes after switching PCSK9-targeting therapies in heterozygous familial hypercholesterolemia: the SHIFT-FH study.
Journal: Internal and emergency medicine
Published: March 23, 2026
Last Updated: 06/30/2026